Why Structure Therapeutics Stock Was Stumbling This Week

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (NASDAQ: GPCR), was a victim of a general rout in the segment. According to data compiled by S&P Global Market Intelligence the company's share price had eroded by 11%, largely because of a single TV commercial.On Sunday, telehealth company and pharmaceutical retailer Hims & Hers Health splurged with a multimillion-dollar ad buy during the Super Bowl. The somewhat alarmist commercial -- "obesity is America's deadliest epidemic," intoned the narrator -- touted one of the higher-potential Hims & Hers' offerings, its compounded semaglutide weight loss treatment. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool